Literature DB >> 27346210

Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders.

Natchaya Vanwong1,2, Santirat Prommas1,2, Apichaya Puangpetch1,2, Yaowaluck Hongkaew1,2, Nopadol Nuntamool1,2,3, Chalitpol Na Nakorn1,2,4, Nattawat Ngamsamut5, Penkhae Limsila5, Chonlaphat Sukasem6,7.   

Abstract

BACKGROUND: Risperidone (RIS) is a widely used atypical antipsychotic drug. We developed and validated a sensitive and accurate LC-MS/MS method, which requires a small-volume of plasma and small-volume injection for measurement of RIS levels in ASD pediatric patients. We also investigated the relationship between RIS levels and RIS dosages, including prolactin levels.
METHOD: Blood samples were processed by protein precipitation extraction. Only 1 μl of sample was injected. Plasma samples were separated on a C18 column (4.6 cm × 50 mm; 1.8 μm particle size). Detection was by MS-MS with an analytical run time of 6 min.
RESULTS: The inter-day accuracy of RIS was 101.33-107.68% and 95.24-103.67% for 9-OH-RIS. The inter-day precision of RIS was ≤7.27% CV and ≤7.41% CV for 9-OH-RIS. The extraction recovery of RIS and 9-OH-RIS were 95.01 ± 7.31-112.62 ± 7.50% and 90.27 ± 11.15-114.00 ± 10.35%, respectively. This method was applied in the therapeutic drug monitoring of ASD pediatric patients. Higher RIS dosage has a tendency to produce higher RIS plasma levels. The high RIS plasma levels have a tendency to produce hyperprolactinemia.
CONCLUSION: The determination of RIS in individual patients might be clinically useful for monitoring and prediction of treatment response.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  9-hydroxyrisperidone; Autism spectrum disorders; LC-MS/MS; prolactin; risperidone

Mesh:

Substances:

Year:  2016        PMID: 27346210      PMCID: PMC6807077          DOI: 10.1002/jcla.22009

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  27 in total

1.  High-performance liquid chromatographic method with diode array detection to identify and quantify atypical antipsychotics and haloperidol in plasma after overdose.

Authors:  K Titier; S Bouchet; F Péhourcq; N Moore; M Molimard
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-05-05       Impact factor: 3.205

2.  Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia.

Authors:  T Nagasaki; T Ohkubo; K Sugawara; N Yasui; H Furukori; S Kaneko
Journal:  J Pharm Biomed Anal       Date:  1999-03       Impact factor: 3.935

3.  Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS.

Authors:  B Cabovska; S L Cox; A A Vinks
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-15       Impact factor: 3.205

4.  Biochemical profile of risperidone, a new antipsychotic.

Authors:  J E Leysen; W Gommeren; A Eens; D de Chaffoy de Courcelles; J C Stoof; P A Janssen
Journal:  J Pharmacol Exp Ther       Date:  1988-11       Impact factor: 4.030

5.  Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology.

Authors:  Christopher J McDougle; Lawrence Scahill; Michael G Aman; James T McCracken; Elaine Tierney; Mark Davies; L Eugene Arnold; David J Posey; Andrès Martin; Jaswinder K Ghuman; Bhavik Shah; Shirley Z Chuang; Naomi B Swiezy; Nilda M Gonzalez; Jill Hollway; Kathleen Koenig; James J McGough; Louise Ritz; Benedetto Vitiello
Journal:  Am J Psychiatry       Date:  2005-06       Impact factor: 18.112

Review 6.  Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?

Authors:  Katherine Seto; Jane Dumontet; Mary H H Ensom
Journal:  Ther Drug Monit       Date:  2011-06       Impact factor: 3.681

7.  Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.

Authors:  Buster Mannheimer; Christer von Bahr; Hans Pettersson; Erik Eliasson
Journal:  Ther Drug Monit       Date:  2008-10       Impact factor: 3.681

8.  Risperidone in children with autism and serious behavioral problems.

Authors:  James T McCracken; James McGough; Bhavik Shah; Pegeen Cronin; Daniel Hong; Michael G Aman; L Eugene Arnold; Ronald Lindsay; Patricia Nash; Jill Hollway; Christopher J McDougle; David Posey; Naomi Swiezy; Arlene Kohn; Lawrence Scahill; Andres Martin; Kathleen Koenig; Fred Volkmar; Deirdre Carroll; Allison Lancor; Elaine Tierney; Jaswinder Ghuman; Nilda M Gonzalez; Marco Grados; Benedetto Vitiello; Louise Ritz; Mark Davies; James Robinson; Don McMahon
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

9.  Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers.

Authors:  Ming-zhu Huang; Jian-zhong Shentu; Jun-chun Chen; Jian Liu; Hui-li Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2008-02       Impact factor: 3.066

10.  Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia.

Authors:  Jeffrey R Bishop; Mani N Pavuluri
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

View more
  3 in total

1.  Resolving discordant CYP2D6 genotyping results in Thai subjects: platform limitations and novel haplotypes.

Authors:  Yaowaluck Hongkaew; Wendy Y Wang; Roger Gaedigk; Chonlaphat Sukasem; Andrea Gaedigk
Journal:  Pharmacogenomics       Date:  2021-05-17       Impact factor: 2.638

2.  Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.

Authors:  Sadeep Medhasi; Darawan Pinthong; Ekawat Pasomsub; Natchaya Vanwong; Nattawat Ngamsamut; Apichaya Puangpetch; Monpat Chamnanphon; Yaowaluck Hongkaew; Jirawat Pratoomwun; Penkhae Limsila; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2016-12-02       Impact factor: 5.810

3.  Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone.

Authors:  Yaowaluck Hongkaew; Andrea Gaedigk; Bob Wilffert; Nattawat Ngamsamut; Wiranpat Kittitharaphan; Penkhae Limsila; Chonlaphat Sukasem
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.